6 August 2025

Nanosonics receives US FDA clearance for next generation trophon® technology

- US Food and Drug Administration (FDA) clearance received for latest trophon innovation, enabling launch of trophon3 and trophon2 *Plus* in the US.
- Offers customers over 40% faster cycle time, greater digital integration and the broadest traceability capabilities.
- trophon3 to drive further penetration into the hospital and private physician markets representing ~30,000 new device opportunity in the US.
- Launch also represents significant global upgrade opportunity with ~10,000 first generation trophon EPR devices for upgrade to third generation trophon3, in addition to ~20,000 trophon 2 devices for the trophon2 *Plus* software upgrade package.

Nanosonics Limited (ASX: NAN), a leader in infection prevention, announces it has been granted clearance from the US FDA for its latest trophon® innovation, enabling the Company to commercially launch trophon3 and trophon2 Plus, a software upgrade package for existing trophon 2 users, in the US.

trophon3 delivers a range of new benefits to customers while maintaining the highest standard in clinical efficacy for patient safety. The new innovation is over 40% faster than previous generations. It has expanded digital integration capabilities and offers the widest traceability capabilities in the ultrasound reprocessing market including new digital traceability through customer's DICOM imaging database systems, the international standard for medical imaging data. Fully programmable and adaptable, trophon3 can be customised to suit a range of customer workflows enhancing efficiency while delivering consistent, reliable disinfection in a safe, effective, and environmentally friendly way.

trophon3 is expected to support continued growth in the Company's installed base in both the hospital and private physician market segments, as well as drive a significant upgrade opportunity for approximately 10,000 original trophon EPR devices. trophon2 *Plus* is a software upgrade package that enables existing trophon2 users to access the key new features of trophon3. With approximately 20,000 trophon2 devices globally, this new package represents a significant software upgrade opportunity.

"The FDA clearance and USA launch of trophon3 and trophon2 *Plus* mark important milestones for Nanosonics. These innovations set a new benchmark in automated high-level disinfection and unlock significant growth opportunity through both new installed base and upgrades," said Michael Kavanagh, CEO and President.

Authorised by the Chairman of Nanosonics Limited.

For more information, please contact:
Catherine Strong, Head of Investor Relations and Corporate Communications
+61 (0)406 759 268, c.strong@nanosonics.com